Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.
2.

Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging.

Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaître M, Duquesnoy S, Garot J, Roques BP, Michel JB, Corot C, Ballet S.

Mol Pharm. 2012 Apr 2;9(4):850-61. doi: 10.1021/mp2003863. Epub 2012 Mar 8.

PMID:
22352457
3.

MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor.

Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA.

Magn Reson Med. 2006 Sep;56(3):601-10.

4.

A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content.

McAteer MA, Mankia K, Ruparelia N, Jefferson A, Nugent HB, Stork LA, Channon KM, Schneider JE, Choudhury RP.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1427-35. doi: 10.1161/ATVBAHA.111.241844. Epub 2012 Apr 12.

5.

Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis.

Cormode DP, Chandrasekar R, Delshad A, Briley-Saebo KC, Calcagno C, Barazza A, Mulder WJ, Fisher EA, Fayad ZA.

Bioconjug Chem. 2009 May 20;20(5):937-43. doi: 10.1021/bc800520d.

6.

Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state.

Liu Q, Hamblin MR.

Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):391-402.

7.

Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles.

Shen ZT, Zheng S, Gounis MJ, Sigalov AB.

PLoS One. 2015 Nov 16;10(11):e0143453. doi: 10.1371/journal.pone.0143453. eCollection 2015.

8.

Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging.

You DG, Saravanakumar G, Son S, Han HS, Heo R, Kim K, Kwon IC, Lee JY, Park JH.

Carbohydr Polym. 2014 Jan 30;101:1225-33. doi: 10.1016/j.carbpol.2013.10.068. Epub 2013 Oct 26.

PMID:
24299895
9.

Biocompatible KMnF3 nanoparticular contrast agent with proper plasma retention time for in vivo magnetic resonance imaging.

Liu ZJ, Song XX, Xu XZ, Tang Q.

Nanotechnology. 2014 Apr 18;25(15):155101. doi: 10.1088/0957-4484/25/15/155101. Epub 2014 Mar 18.

PMID:
24642699
10.

Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10.

Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C.

Invest Radiol. 2004 Jan;39(1):56-63.

PMID:
14701989
11.

Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging.

Maiseyeu A, Mihai G, Roy S, Kherada N, Simonetti OP, Sen CK, Sun Q, Parthasarathy S, Rajagopalan S.

Nanomedicine (Lond). 2010 Nov;5(9):1341-56. doi: 10.2217/nnm.10.87.

12.

Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI.

Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):961-6. Epub 2007 Jan 10.

13.

Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization.

Wagner S, Schnorr J, Ludwig A, Stangl V, Ebert M, Hamm B, Taupitz M.

Int J Nanomedicine. 2013;8:767-79. doi: 10.2147/IJN.S38702. Epub 2013 Feb 20.

14.

PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc).

Bigalke B, Phinikaridou A, Andia ME, Cooper MS, Schuster A, Wurster T, Onthank D, Münch G, Blower P, Gawaz M, Nagel E, Botnar RM.

Int J Cardiol. 2014 Nov 15;177(1):287-91. doi: 10.1016/j.ijcard.2014.09.017. Epub 2014 Sep 22.

PMID:
25499394
15.

Use of contrast enhancement and high-resolution 3D black-blood MRI to identify inflammation in atherosclerosis.

Hur J, Park J, Kim YJ, Lee HJ, Shim HS, Choe KO, Choi BW.

JACC Cardiovasc Imaging. 2010 Nov;3(11):1127-35. doi: 10.1016/j.jcmg.2010.08.012.

16.

Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

Caravan P.

Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p.

PMID:
19222207
17.

Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor.

Tawakol A, Castano AP, Gad F, Zahra T, Bashian G, Migrino RQ, Ahmadi A, Stern J, Anatelli F, Chirico S, Shirazi A, Syed S, Fischman AJ, Muller JE, Hamblin MR.

Photochem Photobiol Sci. 2008 Jan;7(1):33-9. doi: 10.1039/b710746c. Epub 2007 Oct 29.

18.

Scavenger-receptor targeted photodynamic therapy.

Hamblin MR, Miller JL, Ortel B.

Photochem Photobiol. 2000 Oct;72(4):533-40.

PMID:
11045726
19.

Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis.

Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, Abbate A, Aguinaldo JG, Massey D, Fuster V, Vetrovec GW, Fayad ZA.

JACC Cardiovasc Imaging. 2009 May;2(5):637-47. doi: 10.1016/j.jcmg.2008.08.009.

20.

The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs.

Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, Murata T, Otagiri M.

Biochim Biophys Acta. 2007 Dec;1772(11-12):1192-8. Epub 2007 Oct 17.

Supplemental Content

Support Center